The course and outcome of Friend virus complex (FV)l-induced erythroleukemia is influenced by several mouse genes (1, 2). Spontaneous recovery from leukemia occurs in certain strains of mice (3, 4) and appears to be a complex phenomenon requiring the interaction of several mechanisms controlled by different genes (5, 6). For example, genes associated with the mouse major histocompatibility complex (H-2) interact in a complementary manner with at least one non-H-2 gene (Rfv-3) to produce a high incidence of recovery from leukemia (7, 8) . In the absence of the appropriate high recovery H-2 genotype, the Rfv-3 gene influences recovery from viremia in spite of progressive fatal leukemia (8).
with FV, plasm~i F-MuLV was high (>10 a PFU/ml) in only 3 of 39 mice (Table I) and leukemic spleen cells from only 1 mouse had high levels of membrane immunofluorescence (>50% positive) (Table I ). In addition, most mice (34/43) had cytotoxic anti-FV leukemia cell antibodies, which were capable of lysing early (8-9 d), but not late (30-90 d), leukemic spleen cells (Table I) . Similar results for viremia, loss of FV antigen, and presence of anti-FV antibody were seen with (B10.A × A.BY)F1 mice (data riot shown).
Viremia, FV Antigen Retention, and Absence of Anti-FV Antibody in A.BY and A/WySn
Mice. In contrast to the Fa mice, A.BY and A mice did not recover from viremia. 35-37 d after FV inoculation, 18 of 21 mice still had >10 a PFU/ml plasma F-MuLV (Table I ). In addition, most A.BY and A mice (19/21) did not exhibit a loss of FVinduced cell-surface antigens in late stages of the leukemia (Table I) . Finally, most A.BY and A mice failed to develop demonstrable cytotoxic anti-FV antibodies during late stages of the disease (only 2 of 23 had titers _>4) ( Table I) . The difference in recovery from viremia between (B10.A × A)Fx and A strains was previously determined to be influenced by a non-H-2 gene, Rfv-3 (8) . To determine whether the loss of FV-induced cell-surface antigens and production of cytotoxic anti-FV antibodies were under similar genetic control, individual (B10.A X A)Fa × A backeross mice were studied.
Comparison of F-MuL V Viremia, FV-Induced Cell-Surface Antigens, and Anti-FV Antibody in (BIO.A × A)Fx X A Backcross
Mice. Plasma and spleens were collected from backcross mice 35-37 days after FV inoculation. Plasma F-MuLV levels in backcross mice segregated nearly equally between high (> 103 PFU/ml) (24 mice) and low (< 10 a PFU/ml) (27 mice) (Table I) . A similar segregation was seen for FV cell-surface antigen loss; 27 mice had low nun~bers of cells (<50%) with FV-induced cell-surface antigens and 24 mice had high (>50% positive) levels of membrane immunofluoreseence (Table I) . Fig. 1 (left column) shows the distribution of membrane immunofluorescence values for the backcross mice and demonstrates the existence of two groups corresponding to the Fa and A parents. Cytotoxic anti-FV antibody also segregated nearly equally between high and low levels. 22 mice had titers of <4, and 28 had titers -->4 (Table I) . Therefore, recovery from viremia, loss of FV-induced cell-surface antigens, and generation of cytotoxic anti-FV antibody were each influenced by a single genetic locus.
By comparing these three parameters in individual backcross mice, we determined that all three were influenced by the same gene, Rfv-3. A strong association was found between recovery from viremia, loss of FV-induced cell-surface antigens, and presence of anti-FV antibody (Table II) . Mice which had high plasma F-MuLV (>103 PFU/ ml) were usually found to have high virus-specific immunofluorescence. Mice which had low plasma F-MuLV (<103 PFU/ml) were typically found to have low virusspecific membrane immunofluorescence. Similarly, the presence of cytotoxic anti-FV antibodies in plasma from leukemic mice was associated with low plasma F-MuLV levels and with low incidences of virus-specific immunofluorescent-positive cells in spleens. Low cytotoxic anti-FV antibody titers in plasma from leukemic backcross mice were associated with high plasma F-MuLV levels and with high percent virusspecific membrane fluorescence on spleen cells. Thus, approximately one-half of the backcross mice were similar to the (B10.A × A)F1 parents and appeared to have the dominant B10.A allele of the Rfv-3 gene associated with recovery from viremia, loss of FV-induced cell-surface antigens, and generation of cytotoxic anti-FV antibody. The other half of the backcross mice were similar to the A strain and appeared to lack the B10.A allele of Rfv-3. %.: 
Kinetics of anti-FV
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were examined for membrane immunofluorescence and anti-FV antibody at various times after FV inoculation. The percent of spleen cells with FV-induced cell-surface antigens increased rapidly to a plateau (60-70% positive in the fluorescent antibody assay) which persisted from about day 8 to around day 20 after FV injection. Thereafter, the percentage of positive cells decreased to levels characteristic of late spleens (Fig. 2) . Starting on about day 21, anti-FV antibody was first detected in plasma of leukemic mice. Some mice with demonstrable antibody still had a high percent of cells with FV cell membrane antigen. However, the close association between antibody production and antigen loss supports the hypothesis that anti-FV antibody is involved in the induction of antigen loss. (30-32%), whereas spleens from mice which had received normal mouse serum or no serum at all, had high percentages of positive cells (57-69%) (Table III ). All spleens examined had high levels of virus-specific cytoplasmic immunofluorescence (60-74%), indicating that the immune serum had not specifically eliminated virus-infected cells. These results strongly suggest that immune serum induces virus-specific cell-surface antigen loss in vivo.
Loss of FV Antigens after
FVAntigen Loss on A.BYLeukemi¢ Cells. A.BY leukemic spleen cells do not normally lose FV antigens during the course of FV leukemia (Table I , Fig. 1 ). We wanted to know whether the failure of A.BY mice to produce anti-FV antibody could be responsible for FV-antigen retention, or whether A.BY leukemic spleen cells were intrinsically resistant to modulation of FV antigens. Therefore, high antigen A.BY to lethally irradiated (900 rads) (B10.A X A.BY)Fj mice. These cells were 68% positive in the membrane immunofluorescence assay. 0.5 ml of either anti-FV serum or normal B10.A mouse serum (NMS) was administered on days 5 and 6 after cell transfer, and on day 7 spleens were harvested. Spleen cells were tested for cell-surface and intracellular (cytoplasmic) virus-specific immunofluorescence. spleen cells were exposed to anti-FV antibody by transfer to lethally irradiated hyperimmune (B 10.A × A.BY)Fa recipients. It was observed that early A.BY leukemic spleen cells lost FV-specific cell-surface antigens 6 d after transfer (Table IV) . Because these cells were capable of FV antigen loss, this data suggested that lack of production of anti-FV leukemia cell antibody was responsible for the high FV cell-surface antigen levels seen in A.BY mice in late stages of leukemia. (9) and A.BY leukemic spleen cells could be induced to lose FV antigen upon transfer to lethally irradiated hyperimmune mice which had demonstrable cytotoxic anti-FV plasma antibody. (c) Adoptive transfer of early (B10.A × A)F1 (high antigen) spleen cells to lethally irradiated recipients, followed by passive transfer of anti-FV immune serum, provided direct evidence that anti-FV antiserum was capable of inducing FV-antigen loss from leukemic spleen cell surfaces. It appeared that antibody was acting to modulate FVinduced cell-surface antigens (14-18) and was not simply killing virus-infected cells, because the spleen cells retained intracellular virus-specific antigens. Furthermore, because immune serum was transferred 1 and 2 d before spleen cells were examined, it would appear highly unlikely that a population of low FV cell-surface antigen cells could have overgrown the spleen in that time.
TABLE IV

FV-Induced Cell-Surface Antigen Loss on Early (8-9 D) A.BY Leukemic Spleen Cells Transferred to Lethally Irradiated Immune Recipients
If the mechanism of Rfv-3r/~-associated antigen loss operates via control of the production of anti-FV antibodies, then one would expect that if high antigen leukemic spleen cells from A or A.BY mice (Rfv-3 ~/') were introduced into an environment with anti-FV antibodies, they would lose FV cell-surface antigens. This was observed upon the transfer of high antigen A.BY spleen cells to lethally irradiated hyperimmune recipients. These results suggested that the failure of A.BY leukemic spleen cells to lose FV antigen during the normal disease course was not a result of an intrinsic inability of A.BY cells to lose (or modulate) antigen. It seemed likely that FV antigen was not lost after 30 d postinoculation because A.BY mice were not capable of generating anti-FV leukemia cell antibodies. 2 Interestingly, although the A.BY and A mice usually do not produce cytotoxic anti-FV leukemia cell antibodies late in the disease, they do develop significant FVneutralizing antibody titers (B. Chesebro. Manuscript in preparation). It may be that clearance of virus from plasma by neutralizing antibody is not sufficient to effect recovery from viremia. Apparently, anti-leukemia cell antibodies are required to decrease virus production. Because cell-surface FV gp70 may be essential for recognition of viral cores before virus budding, antibody-mediated modulation or dispersion of cell-surface viral proteins could interfere with virus budding and release (19) . Although we think it most likely that Rfv-3 acts as an immunoregulatory gene (20) , that influences production of cytotoxic anti-FV antibodies, other possibilities exist. Rfv-3 r/~ could act to increase interferon production (21, 22) , which would decrease virus production, and in turn, FV-antigen expression. Alternately, Rfv-3 r/s could increase production of SFFV defective interfering particles, which could contribute to recovery from F-MuLV viremia (23) . Kumar et al. (24) have demonstrated the existence of a gene (FV-3) which confers resistance to nonspecific immunosuppression induced by FV. Rfv-3 may similarly regulate susceptibility to immunosuppression (25) but is not likely to be identical to FV-3 because Rfv-3 r is dominant for antibody production, and FV-3" is dominant for susceptibility to immunosuppression.
Several mouse genes were recently shown to influence MLV viremia and leukemia (26) . Because FV and MLV are immunologically cross-reactive, it would seem likely that any mouse genes which influence immunological recognition of FV or MLV antigens might be of importance to both systems. However, at present it appears that Rfv-3 has no influence on MLV viremia as B10 and A.BY mice, which differ at Rfv-3, have similar responses to MLV (26) .
Wheelock et al. (27) have suggested that statolon-induced anti-FV antibody may induce both regression of FV splenomegaly and antigenic modulation of FV antigens which could lead to the persistence of leukemia cells. Our results confirmed that FV leukemia cells could persist in the presence ofcytotoxic antibody, and FV cell-surface antigens were quantitatively decreased on these leukemia cells (9) . However, antibody alone appeared unable to induce regression of massive splenomegaly. Furthermore, our preliminary experiments indicate that low antigen late leukemic Fx spleen cells grow in hyperimmune recipient mice (data to be published). It seems likely that other mechanisms such as cell-mediated cytotoxicity (CMC) may be necessary for recovery from splenomegaly (28) . It remains unclear whether modulation of cell-surface antigens has any bearing on growth of tumor cells in the face of a tumor-specific immune response. Antibody-induced antigenic modulation may interfere with CMC or other host defense mechanisms essential for elimination of tumor. If so, the kinetics of the CMC response compared with the antibody response would be of critical importance to whether or not recovery from leukemia ultimately occurs. 
